Jasper Therapeutics

44 articles with Jasper Therapeutics

• Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer

  3/23/2023

  Jasper Therapeutics, Inc. today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer.

• Jasper Therapeutics to Present at Upcoming Conferences - March 09, 2023

  3/9/2023

  Jasper Therapeutics, Inc. announced that the Company will be participating in the following conferences in March.

• Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update

  3/8/2023

  Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced results for the fiscal year ended December 31, 2022, and provided a business update.

• Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

  2/17/2023

  Jasper Therapeutics, Inc. announced new positive Phase 1 data on briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant.

• Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

  2/17/2023

  Jasper Therapeutics, Inc. announced the appointment of healthcare industry veteran Vishal Kapoor, Partner of Avego Management, to Jasper’s Board of Directors.

• Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

  2/17/2023

  Jasper Therapeutics, Inc. announced that new follow-up data from Jasper’s investigator-sponsored study of briquilimab as a conditioning agent in the treatment of Fanconi Anemia were presented in a poster presentation today at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR taking place in Orlando, Florida.

• Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

  2/16/2023

  Jasper Therapeutics, Inc. announced that additional follow-up data from Jasper’s investigator-sponsored study of briquilimab as a conditioning agent in the treatment of sickle cell disease were presented in a plenary session focused on novel antibody-based conditioning regimens at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

• Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  2/3/2023

  Jasper Therapeutics, Inc. announced that, on February 2, 2023, it granted an option to purchase 1,093,831 shares of Jasper’s voting common stock to Ronald Martell, Jasper’s President and Chief Executive Officer.

• Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023

  1/30/2023

  Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”) announced today that it will host an investor conference call and webcast to provide a corporate update on Tuesday, January 31 from 8:30 am – 9:30 am Eastern Time.

• Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  1/27/2023

  Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”) announced today the closing of its previously announced underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50 per share.

• Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

  1/25/2023

  Jasper Therapeutics, Inc. announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock.

• Jasper Therapeutics Announces Proposed Public Offering of Common Stock - Jan 24, 2023

  1/24/2023

  Jasper Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

• Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

  1/13/2023

  Jasper Therapeutics, Inc. today announced that new positive data for briquilimab (formerly known as JSP191), will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.

• Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

  1/10/2023

  Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem cell transplant conditioning agents targeting c-Kit, today announced, as part of an overall portfolio prioritization, that the Company will focus on the development of its lead product candidate, briquilimab (formerly known as JSP191), in chronic diseases and stem cell transplant for rare diseases.

• Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant

  1/4/2023

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic cell transplant (HCT) therapies, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT.

• Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

  1/3/2023

  Jasper Therapeutics today announced positive clinical data from the first three participants in an investigator-initiated Phase 1/2 clinical trial (NCT05357482) evaluating the addition of briquilimab.

• Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/10/2022

  Jasper Therapeutics, Inc., a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, announced third quarter 2022 financial results and provided a corporate update.

• Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

  9/26/2022

  Jasper Therapeutics, Inc. today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at the annual conference of the Inborn Errors Working Party.

• Jasper Therapeutics to Present at Upcoming Conferences

  9/23/2022

  Jasper Therapeutics, Inc. today announced that the Company will be participating in the following conferences in September.

• 

  FDA Review: Abiomed, Mallinckrodt, Aro and More

  9/16/2022

  The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.